Based on these findings, LAT-1 inhibition could be considered a potential strategy for metastasis prevention in patients with a more aggressive disease (i.e., grade 3 neuroendocrine tumors), which is usually more dependent on amino acid and glucose metabolism. The gene discussed is SLC7A5; the disease is neuroendocrine neoplasm.